Contact

Additional Info

  • Other Names:
    Hootman

All Publications

  • A NOVEL VALIDATED CHECKLIST FOR VIDEOLARYNGOSCOPY REVIEW Hootman, J., Staggenborg, K., Hennessey, E. LIPPINCOTT WILLIAMS & WILKINS. 2024

    View details for Web of Science ID 001131541101554

  • Retrospective Review of the Efficacy of Droperidol Compared to Prochlorperazine for Headache Management in the Emergency Department. Cureus Driller, G. K., Remigio, A., Teng, J., Fang, A., Hootman, J., Chang, A. 2023; 15 (6): e39848

    Abstract

    Introduction Headaches are a common presentation to the emergency department, representing approximately 3% of visits. The standard treatment of headaches has consisted of either monotherapy with an antidopaminergic agent or combination therapy with an antidopaminergic agent, a non-steroidal anti-inflammatory drug (NSAID), and diphenhydramine. Although droperidol is an antidopaminergic medication, it previously was not widely used in the treatment of headaches due to safety concerns. Given its pharmacokinetics, droperidol may provide faster relief in migrainous headaches compared to more commonly used antidopaminergic agents. Methods We conducted a single-center retrospective chart review to examine the impact of droperidol compared to other standard migraine therapies on pain scores. The study consisted of three treatment arms: droperidol monotherapy, a droperidol bundle (droperidol and ketorolac), and a prochlorperazine bundle (prochlorperazine and ketorolac). Patients who received medications in treatment arms and who had an encounter diagnosis including either "headache" or "migraine" were included. Patients were excluded if under 18 years of age, imprisoned, pregnant, or received potentially migraine-altering medications prior to the first documented pain score. The primary outcome was a mean reduction in pain scores. Secondary outcomes included length of emergency department stay, rates of inpatient admission, need for rescue therapies, and adverse events. Results A total of 361 droperidol orders were reviewed, of which 79 met the inclusion criteria. Of those included, 30 orders were within the droperidol monotherapy arm, 19 were within the droperidol bundle arm, and 30 were within the prochlorperazine bundle arm. There were no significant differences in reduction of pain scores, emergency department length of stay, rates of inpatient admission, rates of rescue therapy, or adverse events between the three treatment arms. Conclusion In this study, we found no statistical difference in migraine treatment efficacy between droperidol monotherapy and droperidol and prochlorperazine-based bundle therapies. Further studies are needed with larger sample sizes and predefined timing between pain score charting and medication administration.

    View details for DOI 10.7759/cureus.39848

    View details for PubMedID 37404431

    View details for PubMedCentralID PMC10314824

  • Understanding Physician Trainee Attitudes and Knowledge of Inferior Vena Cava Ultrasound Ramaswamy, T., Hootman, J., Wilson, J., Rogers, A. AMER THORACIC SOC. 2022

    View details for Web of Science ID 000792480404155

  • ADJUNCT VASOPRESSIN IN CARDIOGENIC SHOCK IS ASSOCIATED WITH INCREASED MORTALITY Hootman, J., Bentley, M., Sane, D. LIPPINCOTT WILLIAMS & WILKINS. 2018: 56

    View details for DOI 10.1097/01.ccm.0000528167.66697.47

    View details for Web of Science ID 000436794300112